Journal
CANCERS
Volume 13, Issue 15, Pages -Publisher
MDPI
DOI: 10.3390/cancers13153783
Keywords
Ewing sarcoma; EWSR1-FLI1; CRISPR; Cas9; gene therapy; cell cycle arrest; senescence
Categories
Funding
- Instituto de Salud Carlos III [PI20CIII/00020, DTS18CIII/00005, PI16CIII/00026]
- Asociacion Pablo Ugarte [TRPV205/18, TPI-M 1149/13]
- Asociacion Candela Riera [TVP333-19, TVP-1324/15]
- Spanish Center for Biomedical Network Research on Rare Diseases (CIBERER) [ER19P5AC728/2021]
- Regional Government of Madrid (CAM) [B2017/BMD3721]
- Asociacion Todos Somos Ivan [TVP333-19, TVP-1324/15]
- Fundacion Sonrisa de Alex [TVP333-19, TVP-1324/15]
- ASION [TVP141/17]
Ask authors/readers for more resources
Ewing sarcoma is an aggressive bone cancer affecting children and young adults, characterized by chromosomal translocations producing chimeric oncogenic transcription factors. In this study, genetic inactivation of the EWSR1-FLI1 oncogene using CRISPR/Cas9 technology in Ewing sarcoma cells effectively blocked cell proliferation and induced a senescence phenotype. This suggests that complete inactivation of EWSR1-FLI1 at the cellular level could be a promising therapeutic approach in the future.
Simple Summary Ewing sarcoma is an aggressive tumor with still unacceptable survival rates, particularly in patients with metastatic disease and for which it is necessary to develop new and innovative therapies. These tumors are characterized by the presence of chromosomal translocations that give rise to chimeric transcription factors (i.e., EWSR1-FLI1) that govern the oncogenic process. In this article, we describe an efficient strategy to permanently inactivate the EWSR1-FLI1 oncogene characteristic of Ewing sarcoma using CRISPR/Cas9 gene editing technology. Although the application of gene therapy in cancer still has many limitations, for example, the strategy for delivery, studies like ours show that gene therapy can be a promising alternative, particularly for those tumors that are highly dependent on a particular oncogene as is the case in Ewing sarcoma. Ewing sarcoma is an aggressive bone cancer affecting children and young adults. The main molecular hallmark of Ewing sarcoma are chromosomal translocations that produce chimeric oncogenic transcription factors, the most frequent of which is the aberrant transcription factor EWSR1-FLI1. Because this is the principal oncogenic driver of Ewing sarcoma, its inactivation should be the best therapeutic strategy to block tumor growth. In this study, we genetically inactivated EWSR1-FLI1 using CRISPR-Cas9 technology in order to cause permanent gene inactivation. We found that gene editing at the exon 9 of FLI1 was able to block cell proliferation drastically and induce senescence massively in the well-studied Ewing sarcoma cell line A673. In comparison with an extensively used cellular model of EWSR1-FLI1 knockdown (A673/TR/shEF), genetic inactivation was more effective, particularly in its capability to block cell proliferation. In summary, genetic inactivation of EWSR1-FLI1 in A673 Ewing sarcoma cells blocks cell proliferation and induces a senescence phenotype that could be exploited therapeutically. Although efficient and specific in vivo CRISPR-Cas9 editing still presents many challenges today, our data suggest that complete inactivation of EWSR1-FLI1 at the cell level should be considered a therapeutic approach to develop in the future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available